Chengdu Kanghong Pharmaceutical Group Co Ltd. Stock Analysis 002773.SZ

Chengdu Kanghong Pharmaceutical Group Co., Ltd. engages in the research, development, production and sale of Chinese patent medicines, chemical medicines and biological products. The company is headquartered in Chengdu, Sichuan and currently employs 4,470 full-time employees. The company went IPO on 2015-06-26. Pharmaceuticals include biological products, traditional Chinese medicines and chemical drugs, and medical devices are mainly ophthalmic medical devices. The firm's products include Conbercept eye injection, Shugan Jieyu capsules, Songling Xuemaikang capsules, Keluoxin capsules, Danshu capsules, Yiqing capsules, venlafaxine hydrochloride sustained-release tablets, aripiprazole orodisintegrating tablets, aripiprazole oral solution, mosapride citrate tablets, mosapride citrate dispersible tablets, s-zopiclone tablets and others, The Company mainly operates its businesses in the domestic and overseas markets.